Collège de France, Paris, France.
Institut Imagine, Paris, France.
C R Biol. 2021 Jun 21;344(1):43-55. doi: 10.5802/crbiol.35.
Vaccination against the SARS-CoV-2, the virus responsible for the Covid-19 pandemic, represents a major infection control strategy in the absence of effective treatment of the disease to date. Unprecedented mobilization has led to the development of a large number of projects, some of which have already been in test in humans for several months. The first efficacy and safety data are expected in the coming weeks. New vaccine technologies are being evaluated (RNA, replicating or non-replicating viral vectors), further increasing the chances of success. The criteria for evaluating vaccines-despite the exceptional speed of their development-must remain rigorous enough to ensure their acceptance by the population. Beyond their development, mass production and equitable distribution raise many questions. Finally, vaccination can only be successfully implemented if health professionals and the population are convinced of its validity, which implies particular attention to the quality of the information given and the methods of communication.
接种 SARS-CoV-2 疫苗是一种主要的传染病控制策略，因为目前还没有有效的治疗方法。空前的动员工作导致了大量项目的开展，其中一些项目已经在人体中进行了数月的测试。预计未来几周内将获得第一批疗效和安全性数据。新的疫苗技术正在评估中（RNA、复制或非复制病毒载体），这进一步增加了成功的机会。尽管疫苗的开发速度非常快，但评估疫苗的标准仍必须足够严格，以确保其被民众接受。除了疫苗的开发之外，大规模生产和公平分配也引发了许多问题。最后，如果卫生专业人员和公众相信疫苗的有效性，那么接种疫苗才能成功实施，这意味着特别需要注意所提供信息的质量和沟通方法。
